US2023149423A1PendingUtilityA1
Compositions comprising omega-3 fatty acids, 17-hdha and 18-hepe and methods of using same
Est. expirySep 3, 2035(~9.1 yrs left)· nominal 20-yr term from priority
C11B 3/001A61K 45/06A61P 29/00A23D 9/00A61K 31/557C11B 1/104C11C 3/10A61K 31/202A23L 33/12
85
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.
Claims
exact text as granted — not AI-modified1 . A composition, comprising:
omega-3 fatty acids present in an amount of about 20% to about 99%, by weight, of the composition; and 18-hydroxy-5Z, 8Z, 11Z, 14Z, 16E-eicosapentaenoic acid (“18-HEPE”), 12-hydroxy-5Z, 8Z, 10E, 14Z, 17Z-eicosapentaenoic acid (“12-HEPE”), and 15-hydroxy-5Z, 8Z, 11Z, 13E, 17Z-eicosapentaenoic acid (“15-HEPE”), wherein 18-HEPE is present in an amount of about 0.02% to about 1%, by weight, of the composition.
2 . The composition of claim 1 , wherein the composition is present in a capsule or in an emulsion.
3 . The composition of claim 1 , wherein the omega-3 fatty acids comprise docosahexaenoic acid (“DHA”) and/or eicosapentaenoic acid (“EPA”).
4 . The composition of claim 1 , wherein the omega-3 fatty acids are in the form of ethyl esters.
5 . The composition of claim 1 , wherein the omega-3 fatty acids are in the form of free fatty acids, esters, mono-glycerides, di-glycerides, tri-glycerides, or mixtures thereof.
6 . The composition of claim 1 , wherein 18-HEPE, 12-HEPE, and/or 15-HEPE are in the form of ethyl esters.
7 . The composition of claim 1 , wherein 18-HEPE, 12-HEPE, and/or 15-HEPE are in the form of free fatty acids, esters, mono-glycerides, di-glycerides, tri-glycerides, or mixtures thereof.
8 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.03% to about 1%, by weight, of the composition.
9 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.04% to about 1%, by weight, of the composition.
10 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.05% to about 1%, by weight, of the composition.
11 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.06% to about 1%, by weight, of the composition.
12 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.07% to about 1%, by weight, of the composition.
13 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.08% to about 1%, by weight, of the composition.
14 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.09% to about 1%, by weight, of the composition.
15 . The composition of claim 1 , wherein 18-HEPE is present in an amount of about 0.1% to about 1%, by weight, of the composition.
16 . The composition of claim 1 , further comprising 5S-hydroxy-6E, 8Z, 11Z, 14Z, 17Z-eicosapentaenoic acid (“5S-HEPE”).
17 . The composition of claim 1 , further comprising 17-hydroxy-4Z, 7Z, 10Z, 13Z, 15E, 19Z-docosahexaenoic acid (“17-H DHA”) and 14-hydroxy-4Z, 7Z, 10Z, 12E, 16Z, 19Z-docosahexaenoic acid (“14-H D HA”).
18 . A dietary supplement, nutraceutical product, nutritional composition for infant formulae and/or prenatal formulae, pharmaceutical composition, vaccine coadjuvant, chemotherapeutic coadjuvant, or medical food composition comprising the composition of claim 1 .
19 . A method of treating inflammation, the method comprising administering the composition of claim 1 to a subject having inflammation.
20 . The method of claim 19 , wherein the inflammation is associated with at least one disease selected from the group consisting of wound healing, sickle-cell disease, arthritis, psoriasis, asthma, pulmonary inflammation, dermatitis, cardiovascular diseases, atherosclerosis, type 2 diabetes, metabolic syndrome, and obesity.Join the waitlist — get patent alerts
Track US2023149423A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.